Atomoxetine
| Atomoxetine | |
|---|---|
| Salts [] | |
|---|---|
| Atomoxetine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 255.35 g/mol [1] |
| Melting point | 161-165 ºC [1] |
| Boiling point | 64-65 ºC at 0.760 mmHg [1] |
| Solubility | 27.8 mg/mL [1] |
| Predicted LogP | 3.7 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H21NO |
| IUPAC name | (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine |
| SMILES | CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2 |
| InChI | InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 |
| InChIKey | VHGCDTVCOLNTBX-QGZVFWFLSA-N |
| CAS number | 83015-26-3 |
| UNII | ASW034S0B8 |
| PubChem CID | 54841 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 1–2 hours (time to peak levels) |
| Elimination half-life | CYP2D6 extensive metabolizers: 4.5–5.3 h, CYP2D6 poor metabolizers: 19–22 h |
| Metabolism | Liver: ring hydroxylation (CYP2D6, others), benzylic hydroxylation, N-demethylation (CYP2C19), glucuronidation (UDP-glucuronyltransferases) |
| Excretion | CYP2D6 extensive metabolizers: urine (>96%), feces (1–2%), CYP2D6 poor metabolizers: urine (80%), feces (13–22%) |
| Routes of administration | Oral |
| Dosing[] |
|---|
| Oral [] | |
|---|---|
| Light | ≤ 25 mg(8x - 66.7%) |
| Common | 25 mg |
| Strong | 25 - 50 mg(4x - 33.3%) |
| Heavy | 50 mg |
| Extreme | 50 mg + |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Atomoxetine (also known as Tomoxetine, (-)-Tomoxetine, Tomoxetina, Tomoxetinum, Tomoxetinum [Latin], Atomoxetina, atomoxetinum, methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine, Tomoxetinum (Latin) or Ad313 component atomoxetine) is a substance of the phenylpropylamine class.
Chemistry
Salts []
Stereochemistry []
Atomoxetine is a single defined stereoisomer (optical activity ( - )).
Druglikeness
Lipinski's rule of five
Atomoxetine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- centrally acting sympathomimetics (N06BA)
- (N06BA09)
- atomoxetine (N06BA09)
MeSH Classification
- adrenergic uptake inhibitors (M0028095)
Mechanism of action []
Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET), which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT), and blocks the N-methyl-d-aspartate (NMDA) receptor, indicating a role for the glutamatergic system in the pathophysiology of ADHD. [1]
Interactions []
Medical side effects []
162 side effects listed on drug labels in SIDER 4.1 (atomoxetine).
- Dry mouth
- Abdominal pain upper
- Headache
- Abdominal pain
- Gastrointestinal pain
- Middle insomnia
- Tachycardia
- Abdominal discomfort
- Upset stomach
- Blood pressure increased
- Epigastric discomfort
- Insomnia
- Decreased appetite
- Anorexia
- Nausea
- Cough
- Vomiting
- Asthenia
- Fatigue
- Dysuria
- Strangury
- Somnolence
- Erectile dysfunction
- Dizziness
- Syncope
- Dysmenorrhoea
- Irritability
- Sinusitis
- Vertigo
- Urinary hesitation
- Mydriasis
- Pruritus
- Urinary retention
- Depressive symptom
- Dysphoria
- Ejaculation failure
- Initial insomnia
- Terminal insomnia
- Major depression
- Libido decreased
- Disturbance in sexual arousal
- Dermatitis
- Rash
- Dyspepsia
- Hyperhidrosis
- Sweating increased
- Abnormal dreams
- Ejaculation disorder
- Nasopharyngitis
- Rhinorrhoea
- Diarrhoea
- Body temperature increased
- Influenza
- Menstrual disorder
- Palpitations
- Paraesthesia
- Prostatitis
- Sinus headache
- Chills
- Rigors
- Myalgia
- Musculoskeletal discomfort
- Arthralgia
- Ejaculation delayed
- Menopausal symptoms
- Hot flush
- Ear infection
- Sleep disorder
- Constipation
- Flatulence
- Orgasm abnormal
- Thirst
- Tremor
- Weight decreased
- Mood swings
- Affect lability
- Menstruation irregular
- Menstruation delayed
- Nervousness
- Feeling jittery
- Therapeutic response unexpected
- Conjunctivitis
- Flushing
- Sinus tachycardia
- Presyncope
- Aggression
- Anxiety
- Mental disorder
- Coma
- Delirium
- Depression
- Hallucination
- Hostility
- Hypoaesthesia
- Lethargy
- Muscle rigidity
- Myoclonus
- Nervous system disorder
- Neuroleptic malignant syndrome
- Pelvic pain
- Psychotic disorder
- Convulsion
- Suicide attempt
- Shock
- Loss of consciousness
- Angiopathy
- Agitation
- Skin disorder
- Autonomic nervous system imbalance
- Mania
- Depressed mood
- Suicidal ideation
- Genital pain
- Drug interaction
- Completed suicide
- Mental status changes
- Erection increased
- Pre-existing disease
- Back pain
- Bone disorder
- Breast disorder
- Chest pain
- Infection
- Drug abuse
- Dysgeusia
- Excoriation
- Gastrointestinal disorder
- Gastrointestinal symptom NOS
- Cardiac disorder
- Mediastinal disorder
- Nasal congestion
- Tension
- Pain
- Muscle spasms
- Testicular pain
- Upper respiratory tract infection
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Pollakiuria
- Micturition urgency
- Sinus congestion
- Viral diarrhoea
- Malnutrition
- Disorientation
- Abnormal behaviour
- Oropharyngeal discomfort
- Oropharyngeal pain
- Peripheral coldness
- Drug dependence
- Vision blurred
- Crying
- Tearfulness
- Dependence
- Urine flow decreased
- Sexual dysfunction
- Infestation
- Laryngeal pain
- Female sexual dysfunction
- Hepatic failure
- Feeling abnormal
- Suicidal behaviour
Indications
- Agitation
- Angle closure glaucoma
- Attention deficit disorder
- Attention deficit/hyperactivity disorder
- Body temperature increased
- Coma
- Delirium
- Epilepsy
- Forgetfulness
- Hepatic insufficiency
- Hyperkinesia
- Hypersensitivity
- Mental disorder
- Mental status changes
- Muscle rigidity
- Mydriasis
- Myoclonus
- Neuroleptic malignant syndrome
- Psychotic disorder
Subjective effects []
| a1ko / Atomoxetine [] | |
|---|---|
Routes:
| |
| Pilz / Atomoxetine [] | |
|---|---|
Routes:
| |
Experience reports
Legal status []
- Australia: Atomoxetine is a Schedule 4.
- Brazil: Atomoxetine is a C1.[3]
- Canada: Atomoxetine is Prescription only.
- New Zealand: Atomoxetine is Prescription only.
- United Kingdom: Atomoxetine is Prescription only.[4]
- United States: Atomoxetine is Prescription only.
- European Union: Atomoxetine is Prescription only.[5]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 54841, Atomoxetine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/54841
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Atomoxetine. UNII: ASW034S0B8. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ASW034S0B8
RDC Nº 816 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 15 September 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-816-de-15-de-setembro-de-2023-510390164
Strattera 10mg hard capsules - Summary of Product Characteristics (SmPC). (emc). 8 February 2021. https://www.medicines.org.uk/emc/product/5531/smpc
Active substance(s): atomoxetine. List of nationally authorised medicinal products. 2016. https://www.ema.europa.eu/en/documents/psusa/atomoxetine-list-nationally-authorised-medicinal-products-psusa/00000262/201511_en.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 14:29:51 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 14:29:47 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 14:29:47 |
| gsrs | ok | 2026-11-20 14:29:48 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014434) | 2026-11-20 14:29:47 |
| kegg | ok | 2026-11-20 14:29:50 |
| pubchem | ok | 2026-11-20 14:29:47 |
| ok | 2026-11-20 14:29:47 | |
| sider | ok | 2026-11-20 14:29:47 |
| structure | ok | 2026-11-20 14:29:47 |
| wikipedia | ok | 2026-11-20 14:29:47 |